Review Paper On: Controlled Delivery of Vaccine

Millions of lives are saved annually by vaccines, which offer significant protection against infectious diseases. The recent COVID-19 pandemic underlined the necessity of vaccination in providing mass-scale immunization against outbreaks. However, because of their enormous molecular size and low stability at room temperature, vaccine distribution presents a special set of difficulties. For the effective development of vaccines, advanced biomaterials and delivery systems including nano- and microscale carriers are increasingly essential. We present an updated overview of current developments in the creation of nano- and micro-scale carriers for the controlled delivery of vaccines in this review, with an emphasis on carriers that work well with the nucleic acid-based treatments and vaccines that have been developed in the wake of the recent pandemic. We first describe delivery systems at the nanoscale, with an emphasis on nanoparticles, and then we discuss systems at the microscale. Self-assembled peptides have demonstrated exceptional properties for medication targeting and vaccine delivery. It is possible to purposefully design peptide molecules so that they will self-assemble into particular nanoarchitectures in response to variations in the conditions under which they assemble, such as temperature, ionic strength, pH, and interactions between host (drug) and guest molecules. The resultant supramolecular nanostructures have a variety of mechanical and physicochemical properties and include hydrogels, nanovesicles, nanofibers, nanotubes, and nanoribbons. By including adhesion ligands, receptor recognition ligands, or peptide-based antigens into their design—often in a multivalent display—these compounds can be engineered for cell-specific targeting. Depending on how they are made, self-assembled peptide nanostructures can be advantageous in terms of adjuvanting, shear-thinning viscoelastic characteristics, encapsulating hydrophobic pharmaceuticals, stability against enzyme degradation, and/or sustained drug release.